Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT05564403
Recruiting
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that have spread to other places in the body (advanced) and had progression of cancer after previous treatments (2nd line setting). Fluorouracil is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +207 locations
Conditions: Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma, Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8
Register for Updates
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
NCT05504837
Recruiting
This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: University of Florida, Gainesville, Gainesville, Florida +4 locations
Conditions: Cystic Fibrosis
Register for Updates
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06236139
Recruiting
This phase I/II trial tests the safety and effectiveness of cell therapy (STEAP1 CART) with enzalutamide in treating patients with prostate cancer that continues to grow despite surgical or medical treatments to block androgen production (castration-resistant) and that has spread from where it first started (the prostate) to other places in the body (metastatic). Prostate cancer is the second leading cause of cancer deaths in men. Localized prostate cancer is often curable and even metastatic di... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
NCT05440617
Recruiting
Background: Medical advances have improved survival rates for many cancers and other illnesses. This means that more people are coping with the long-term effects of these treatments. Some treatments can cause female infertility. Ovarian tissue cryopreservation (OTC) may help. Before undergoing a treatment that may damage their fertility, patients may opt to freeze a sample of ovarian tissue. The tissue contains immature egg cells. When thawed, the tissue can be reimplanted. This procedure can h... Read More
Gender:
FEMALE
Ages:
Between 4 years and 35 years
Trial Updated:
08/19/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Acute Ovarian Failure, Infertility, Early Menopause And Infertility In Females After Treatment For Childhood Cancer
Register for Updates
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05554328
Recruiting
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +279 locations
Conditions: Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Register for Updates
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
NCT05640843
Recruiting
The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare how the plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo (an inactive substance that looks like the study supplements) affect butyrate levels in participants' stool.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Emory University (Data Collection Only), Atlanta, Georgia +7 locations
Conditions: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Register for Updates
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
NCT05916313
Recruiting
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful. The purpose of this study is to find out the highest dose of BI 764532 that people with a brain tumour that is positive for DLL3 can tolerate. BI 764532 is an antibody-like molecule that can attach and link together the cancer cells and T-cells of the immune system (DLL3/CD3 bi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: University of California Irvine, Orange, California +11 locations
Conditions: Glioma
Register for Updates
Auditory Prediction and Error Evaluation in the Speech of Individuals Who Stutter
NCT06181149
Recruiting
Stuttering negatively impacts communication and reduces the overall quality of life and well-being of individuals who stutter. This study will provide a strong foundation for developing neural and behavioral interventions for stuttering. Participants will be asked to name pictures, read words/sentences silently or aloud, and listen to speech and nonspeech sounds while their speech, muscle, and brain signals are collected. Some participants may also receive brain stimulation while reading and spe... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
08/19/2025
Locations: Arizona State University, Tempe, Arizona +1 locations
Conditions: Healthy Subjects, Stuttering, Developmental
Register for Updates
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
NCT06049680
Recruiting
Evaluate the risk of developing EFAD and/or PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of parenteral nutrition treatment with SMOFlipid.
Gender:
ALL
Ages:
Between 1 month and 17 years
Trial Updated:
08/19/2025
Locations: Emory University Hospital, Atlanta, Georgia +3 locations
Conditions: Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
Register for Updates
A Study of AT-02 in Subjects With Systemic Amyloidosis.
NCT05951049
Recruiting
This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/19/2025
Locations: Kansas City, Kansas City, Kansas +3 locations
Conditions: Amyloidosis; Systemic
Register for Updates
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
NCT05985161
Recruiting
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Gender:
ALL
Ages:
12 months and above
Trial Updated:
08/19/2025
Locations: Children's Hospital of Los Angeles (Data Collection Only), Los Angeles, California +14 locations
Conditions: Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
Register for Updates
Ketorolac in Upper Extremity Tendinopathy and Arthropathy
NCT05292339
Recruiting
Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures to minimize pain and improve function. Conservative pharmacological management commonly includes corticosteroid and ketorolac injections which have been well investigated as a modality of pain control and improved function in large joint OA. However, fewer studies yielding mixed results on the durat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: Emory Saint Joseph's Hospital, Atlanta, Georgia +3 locations
Conditions: Osteoarthritis, Tendinopathy, Arthropathy
Register for Updates